A randomised phase 3 clinical trial is currently underway to assess the combination of IDH inhibitors with induction, consolidation and maintenance therapies in newly diagnosed IDH-mutant AML patients that are eligible for intensive chemotherapy (NCT03839771). Here, IDH1 is linked to acute myeloid leukemia.